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What's in a Name? "Nuclear
Transplantation" and the Ethics of
Stem Cell Research
MARGARET R. MCLEAN, PH.D.*
Introduction
On January 15, 2002, the California State Advisory Committee
on Human Cloning released its final report, Cloning Californians?,
unanimously recommending that "California should not prohibit but
should reasonably regulate human non-reproductive cloning" based
on the conviction that the "use of this technology offers potential
medical and scientific benefits while not raising many of the same
concerns as human reproductive cloning."' Furthermore, the
Advisory Committee recommended that:
California should regulate all human non-reproductive cloning in
the State, public or private. That regulation should do at least three
things: a) prohibit the use of pre-embryos after development of the
primitive streak, b) ensure that the persons providing cells for this
purpose gave informed consent, and c) require that the research be
permitted by an approved Institutional Review Board ("IRB").
These recommendations concerning the non-reproductive use of
cloning technology seek to balance two important ethical mandates,
to cure disease and to respect pre-embryos as a form of human life.
* Director, Biotechnology and Healthcare Ethics, Markkula Center for Applied
Ethics, Santa Clara University. I would like to thank the members of the California
Advisory Committee on Human Cloning for the collegial-albeit difficult-conversation
in which we engaged from May 1999 to January 2002, especially Tracy Trotter, M.D., with
whom I prepared a working document on human non-reproductive cloning for the
Committee's consideration. That document served as the basis for the discussion of the
science of nuclear transplantation in this paper. I would also like to thank Kristen
Koenekamp for her research support. Finally, gratitude is extended to the staff of the
Hastings Lav Journal for sponsoring a stellar symposium and inviting me to be a part of it.
1. REP. OF THE CAL. ADVISORY COMMITTEE ON HUM. CLONING, CLONING
CALIFORNIANS? 53 HASTINGS L.J. 1145, 1182 (2002), [hereinafter CLONING
CALIFORNIANS?].
2. Id.
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As a member of the Advisory Committee, I supported these
recommendations both as a reasoned and reasonable answer to a
public policy question and as reflective of the opinion of the majority
of Californians as best as it could be discerned. Nonetheless, the
Committee's conclusions are a less than complete answer to the
parallel ethics question in that they do not adequately account for
concerns for social justice and the common good.
In general, discussions about the ethics of non-reproductive
human cloning focus on the tension between obtaining stem cells
from pre-embryos and the promise these cells hold for tissue
engineering, while largely ignoring the larger social context in which
biotechnology in general and medical technology in particular
evolves. In many cases, this is a warranted, conscious omission.
However, I am increasingly concerned that as we rush to grab the
brass ring of potential cure heralded by research on non-reproductive
human cloning, we have not adequately confronted the healthcare
burdens potentially placed on those currently marginalized by
American health care.
Although the Advisory Committee discussed the distributive
justice question, it deserves deeper public consideration. Ethically
sound policy regarding biomedical innovations in California requires
looking through the lens of a larger healthcare picture that includes:
* More than 2 million California children (ages 0-18)-7 million
Californians total-without any form of health insurance;3
* 1.9 million (21%) children-4.7 million Californians total-
living in poverty;
3. E. Richard Brown, California's Growing Uninsured Population and Options to
Expand Coverage, UCLA CENTER FOR HEALTH POL. RES. (May 2000), available at
http://wwv.healthpolicy.ucla.edu. The year 1999 is the latest year for which California
statistics are available. It is important to note that whereas the uninsured rate of children
nationally remained relatively flat (14-15%) nationwide between 1995 and 1998, that of
California's children rose from 17% to 21% over the same time period. The current
economic downturn does not bode well for increasing the numbers of insured Californian
children. In 1999, almost 7 million Californians-20% of the state's inhabitants-were
without health insurance of any kind. DEMOGRAPHIC RES. UNIT, ST. OF CAL. DEP'T OF
FIN., CALIFORNIA CURRENT POPULATION SURVEY REPORT: MARCH 2000 DATA 10
(2001), available at http://www.dof.ca.gov [hereinafter SURVEY REPORT]. Nationwide, the
total percent of uninsured persons of all ages from January through June 2001 was 14.1%;
the total percent of uninsured persons 18 years and under was 11.2%, probably reflecting
the implementation of the State Children's Health Insurance Program (SCHIP). U.S.
DEP'T OF HEALTH & HUM. SERVICES, CENTERS FOR DISEASE CONTROL &
PREVENTION, NATIONAL HEALTH INTERVIEW SURVEY (2002) available at
http://www.cdc.gov/nchs/about/nhis/ released2002O2.htm.
4. See SURVEY REPORT, supra note 3. The federal poverty line for 1999 was $22,500
for a family of two, $28,300 for a family of three, and $34,100 for a family of four, which is
not reflective of the high cost of living in many areas of the state.
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* the increasing inability of physicians to obtain vaccines, such as
tetanus, for routine administration.5
Against this backdrop, I propose to do two things: first, to
provide the scientific and ethical background to the recommendations
of the Advisory Committee regarding human non-reproductive
cloning and, second, to recommend further public policy
considerations regarding such research which take serious account of
informed choice in the public square and duties to social justice.
I. The Language and Science of Stem Cell Research
A. What's in a Name?
In the Advisory Committee's report, Cloning Californians?, the
term "non-reproductive human cloning" refers to procedures for "the
transfer of human cell nuclei into enucleated oocytes to produce
human pre-embryos without implanting the pre-embryos to produce a
human child.",6 The Advisory Committee's choice of phraseology was
deliberate so as to delineate clearly the use of nuclear transfer "to
create early pre-embryos to be used as sources of embryonic stem
cells" 7 for research or tissue engineering from the use of this
technique to produce a child for rearing. Although the Advisory
Committee found the term "non-reproductive human cloning" useful
and preferable to "therapeutic cloning,"8 it now seems prudent to
avoid completely the use of the word "cloning" in conversations
about the use of somatic cell nuclear transfer to create stem cells.
Bert Vogelstein, chair of the National Academy of Sciences
Committee on the Biological and Biomedical Applications of Stem
Cell Research, and his co-authors have proposed the term "nuclear
5. Averting Vaccine Disaster, WASH. POST, Feb. 22, 2002, at A24. Note that the
Centers for Disease Control and Prevention is advising physicians to skip tetanus boosters
for teenagers and adults and to prolong the course of diptheria-pertussis-tetanus (DPT)
vaccine for babies. At least eight of eleven crucial childhood vaccines are in critical
shortage. This is due, at least in part, to the lack of incentives for companies to
manufacture vaccines with low profit margins. A drop in immunization rate poses a far
greater threat to public health than that created by acts of bioterrorism.
6. CLONING CALIFORNIANS?, supra note 1, at 1182. The use of the term "pre-
embryo" by the Advisory Committee was also intentional. "Pre-embryo" is short-hand
for "preimplantation embryo." In vivo an embryo at this stage of development would not
be physically attached to the uterine wall. In the human, implantation typically occurs
eight or nine days after fertilization. See Stem Cells: Scientific Progress and Future
Research Directions, NAT'L INST. OF HEALTH, A-1 (2001) [hereinafter NIH Stem Cell
Report].
7. Id.
8. One reason for preferring "non-reproductive human cloning" to the commonly
used "therapeutic cloning" was that there are, to date, no "therapeutic" applications of
this technology.
July 2002]
HASTINGS LAW JOURNAL
transplantation" for the use of somatic cell nuclear transfer to create
stem cells.9 The term nuclear transplantation "captures the concept
of the cell nucleus and its genetic material being moved from one cell
to another, as well as the nuance of 'transplantation,' an objective of
regenerative medicine."10 Using the term "nuclear transplantation"
could add needed precision to scientific and ethical considerations of
stem cell research. There are several reasons why "nuclear
transplantation" is better than other terms.
First, language means everything in public deliberation and
policy formation about human cloning. In the language of science,
"cloning" refers to the various processes used to copy biological
material-bacteria, chromosomes, or cells for example. Cloning so
understood does not necessarily involve the mechanical transfer of
nuclear genetic material from one cell to another or result in the
formation of genetically identical organisms.
Second, once out of the laboratory and into the public square,
the term "cloning" unfortunately becomes synonymous with using
"somatic cell nuclear transfer" for the purpose of creating offspring.
For example, legislation currently under consideration in the United
States Senate defines "human cloning" as "human asexual
reproduction, accomplished by introducing nuclear material from one
or more human somatic cells into a fertilized or unfertilized oocyte
whose nuclear material has been removed or inactivated so as to
produce a living organism (at any stage of development) that is
genetically virtually identical to an existing or previously existing
human organism. '
The bill then prohibits human cloning so defined. Curiously, if
enacted, a plethora of experimental protocols would be proscribed-
including study of inheritable genetic disease and birth defects-while
leaving it permissible to "clone" a human being through embryo
splitting.12
Third, although there are political reasons for spreading the
"cloning" net broadly, it is best to link the term "cloning" solely with
the goal of the process, that is, making a copy of biological material,
not with the procedure used to attain that aim. As Vogelstein and co-
authors claim:
9. Bert Vogelstein et al., Please don't call it cloning!, 295 SCI. 1237 (2002).
10. Id.
11. Human Cloning Prohibition Act of 2001, S. 1899, 107th Cong. § 301 (2001).
12. Early stage embryos can be split in the laboratory in order to produce two
genetically identical embryos which if implanted and brought successfully to terms would
result in the birth of "identical twins," or "human clones." In equating "cloning" with
"nuclear transfer," Senate Bill 1899, the Brownback bill, seemingly allows for "human
cloning" via embryo splitting while prohibiting all use of nuclear transfer, even that
unassociated with reproduction.
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The goal of creating a nearly identical genetic copy of a human
being is consistent vith the term human reproductive cloning, but
the goal of creating stem cells for regenerative medicine is not
consistent with the term therapeutic cloning. The objective of the
latter is not to create a copy of the potential tissue recipient, but
rather to make tissue that is genetically compatible with that of the
recipient... "[T]herapeutic cloning" is conceptually inaccurate and
misleading, and should be abandoned.13
Finally, although the term "non-reproductive cloning" avoids the
pitfall of disguising potential treatments as actual cures, it nonetheless
invites confusion between creating a copy of a human and making
tissues genetically compatible with a particular human. Paying
attention to terminology would help clarify the significant scientific,
medical, and ethical distinctions between human reproductive cloning
and using nuclear transfer to make stem cells.
B. Somatic Cell Nuclear Transfer and Nuclear Transplantation Therapy
For purposes of this paper, nuclear transplantation is defined as
"the transfer of human cell nuclei into enucleated oocytes to produce
human pre-embryos without implanting the pre-embryos to produce a
human child. 14 It refers to the use of somatic cell nuclear transfer to
create embryonic stem cells-initially for research purposes,
eventually, it is hoped, for regenerative medical purposes.
Perhaps the most far-reaching potential application of nuclear
transplantation is the generation of cells and tissues that could be
used for so-called "regenerative medicine." Many diseases and
disorders result from tissue destruction or the disruption of cellular
function. Today, donated organs, e.g. kidneys, and tissues, e.g.
cartilage, are often used to replace ailing or destroyed organs and
tissues. Unfortunately, the number of people suffering from organ-
destroying disorders far outstrips the number of organs available for
transplant. In addition, since donated organs differ genetically from
the recipient (unless from an identical twin), powerful drugs must be
used to suppress the recipient's immune response. Pluripotent stem
cells, obtained from human blastocysts and stimulated to develop into
specialized cells, offer the possibility of a renewable source of
replacement cells and tissues to treat a myriad of serious conditions
for which no curative treatment now exists. These include
13. See Vogelstein et al., supra note 9.
14. CLONING CALIFORNIANS?, supra note 1, at 1182. The Advisory Committee
further stipulates that stem cells should be isolated from these pre-embryos only prior to
the formation of the primitive streak. See U.S. DEP'T OF HEALTH, EDUC., & WELFARE
ETHICS ADVISORY BOARD, REPORT AND CONCLUSIONS: HEW SUPPORT OF
RESEARCH INVOLVING HUMAN IN-VITRO FERTILIZATION AND EMBRYO TRANSFER,
101 (1979). This developmental stage is also called the blastocyst. See Research on
Preembryos: Justifications and Limitations, FERTILITY & STERILITY 62S, 63S (1990).
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Parkinson's Disease, Amyotrophic Lateral Sclerosis (Lou Gehrig's
Disease), Alzheimer's dementia, spinal cord injury, stroke, bums,
heart disease, diabetes, retinal degeneration, osteoarthritis, and
rheumatoid arthritis, among others.
There is almost no realm of medicine that might not be touched
by this innovation. For example, the transplantation of healthy heart
muscle cells could provide new hope for patients with chronic heart
disease whose hearts no longer pump adequately. The hope is to
develop heart muscle cells from human pluripotent stem cells and
transplant them into the failing heart muscle in order to augment the
function of the increasingly flaccid heart. Preliminary work in mice
and other animals has demonstrated that healthy heart muscle cells
transplanted into a failing heart successfully repopulate the heart
tissue and work together with the host heart cells to restore adequate
pumping ability. 5
Although this research shows extraordinary promise, there is
much to be done before the promise is realized. Technological
challenges remain before these discoveries can be incorporated into
clinical practice. These challenges, though significant, are not
insurmountable.
First, the triggers of cell specialization in humans must be better
understood in order to reliably and efficiently direct pluripotent stem
cells to become the type(s) of tissue needed for transplantation.
Second, the mechanisms responsible for the "reversal" of cell
specialization following nuclear transplantation must be delineated.
Third, before any cells can be used for transplantation, immune
rejection must be overcome. Because human pluripotent stem cells
derived from embryonic or fetal tissue would be genetically different
from the recipient, the transplant might be rejected by the recipient's
immune system. 6 Research needs to focus on modifying human
pluripotent stem cells to minimize or to eliminate tissue
incompatibility or to create cell and tissue banks with the most
15. See, e.g., Donald Orlic et al., Bone Marrow Cells Regenerate Infarcted
Myocardium, 410 NATURE 701 (2001); A.A. Kocher et al., Neovascularization of Ischemic
Myocardium by Human Bone-marrow-derived Angioblasts Prevents Cardiomyocyte
Apoptosis, Reduces Remodeling and Improves Cardiac Function, 7 NATURE MED. 430
(2001).
16. Some scientists, notably Hans Keirstead of the University of California at Irvine
and Robert Lanza of Advanced Cell Technology in Massachusetts, have stated that the
need for nuclear transplantation in order to thwart immune rejection has been
"overstated." This is especially true in the case of neuro-degenerative conditions such as
Parkinson's disease, paralysis, and multiple sclerosis since the central nervous system is
"immune privileged." The brain and spinal cord have scant immune protection and tissue
transplanted into the central nervous system is less likely to be rejected than tissue
transplanted elsewhere, such as in the heart or pancreas. See Tom Abate, Drugs Posited
As Stand-in For Stem Cell Cloning, S.F. CHRON., Mar. 18,2002, at El.
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common tissue-type profiles." Finally, the long term ability of
pluripotent stem cells to divide in culture is unknown. It is important
to work out both the molecular mechanism of so-called cellular
"immortality" and to discover if this same mechanism could allow cell
division to run amuck, potentially resulting not in cure but in cancer.
C. Stem Cells-They're Not Just from Plants Anymore
Human embryological development is a matter of exquisite
complexity. '8 Many sorts of laboratory experiments have been
designed to study how fertilization occurs and how a fertilized oocyte
produces a blastocyst, the first instance of cell specialization.
Approximately twenty-four hours after fertilization in vitro, the
fertilized egg, or zygote, goes through its first division to produce two
identical cells and then splits again to produce four cells.
Asynchronous cell division continues producing eight cells, sixteen
cells, and so on-each round of cell division taking approximately
thirty-six hours.'9 By days five and six post-fertilization, the tightly
wound ball of dividing cells develops a cavity. This cell ball is the
blastocyst. It is now evident that cells have specialized. The
blastocyst has an outer rim of cells-the trophectoderm-and an
inner group of cells, the inner cell mass. The cells of the inner cell
mass can give rise to all types of bodily tissue as well as some
17. Although a common argument in support of creating blastocysts for research on
nuclear transplantation-a line of reasoning used by the Advisory Committee in support
of its recommendation on human "non-reproductive cloning"-is the need to create cells
and tissues that will not be rejected by the recipient, it seems highly unlikely that
specifically creating tissues for each and every potential patient-a number in the
hundreds of thousands-will be possible or, indeed, desirable. Simply, it is too expensive,
time consuming, and labor intensive to be scalable. Research underway at Geron
Corporation, and elsewhere, is focusing on the creation of lines of "null" stem cells which
do not possess rejection triggering chemicals on their surface. There is also an effort to
genetically engineer stem cells in order to create viable lines of common tissue type
profiles. Theoretically, the capacity of stem cells to self-replicate would allow these lines
to proliferate indefinitely. Therefore, it might be possible to create tissue banks of both
undifferentiated and specialized cells and tissues. Such cell banks might diminish-and
perhaps ultimately negate-the need for embryonic and fetal tissue, as the stem cell lines
would be self-replicating. Currently, there are banks which store placental and umbilical
cord blood, rich sources of blood-forming-or hematopoietic-stem cells, multipotent
cells which can develop into oxygen carrying red blood cells, infection fighting white blood
cells, and clot promoting platelets. Cells from such banks have been used to treat sickle
cell anemia and leukemia.
18. KEITH L. MOORE & T.V.N. PERSAUD, THE DEVELOPING HUMAN: CLINICALLY
ORIENTED EMBRYOLOGY 29-34 (W.B. Saunders Co., 5th ed., 1993).
19. NIH Stem Cell Report, supra note 6, at A-3.
July 2002]
developmentally supportive tissues 0 The trophectoderm forms part
of the placenta.'
It is at this stage of embryogenesis that human embryonic stem
cells (hES cells) can be derived from the inner cell mass of the
blastocyst. Most of the blastocyst cells are in the outer rim with only
thirty to thirty-four cells in the inner cell mass.' The stem cells in the
inner mass are freed from the outer layer and put in culture to be
grown in the laboratory. It is hoped that under laboratory conditions,
embryonic stem cells can retain two defining characteristics-their
ability to divide for indefinite periods (i.e., self-replication) and their
capacity to give rise to the more than 200 types of specialized cells
making up the human body (i.e., pluripotency) including nerve cells,
muscle cells, skin cells, blood cells.'
In the laboratory, pluripotent stem cells can be derived from
three sources: post-infertility treatment blastocysts, fetal tissue, and
somatic cell nuclear transfer techniques.
The first human embryonic stem cells were derived in 1998.24 In
the work done in the laboratory of Dr. James Thomson, pluripotent
stem cells were isolated directly from the inner cell mass of
blastocysts obtained from infertility clinics. These embryos-
originally made for purposes of reproduction, not research-were in
excess of the clinical need and voluntarily contributed by the gamete
donors. Informed consent was obtained from the donor couples for
this research use. Dr. Thomson isolated the inner cell mass from the
donated blastocysts and produced a pluripotent human stem cell line.
In contrast, Dr. John Gearhart and colleagues isolated
pluripotent stem cells from fetal tissue obtained from terminated
pregnancies. Fetal tissue donors gave informed consent after they
20. It is important to note that although embryonic stem cells are pluripotent (i.e.,
they can develop into all types of body cells), they are not able to generate a body plan or
assemble tissues in an ordered way and, hence, cannot, on their own, develop into an
embryo. See, e.g., Martin F. Pera, Human Pluripotent Stem Cells: A Progress Report, 11
CURRENT OPINION IN GENETICS & DEv. 595,597-98 (2001).
21. NIH Stem Cell Report, supra note 6, at A-3.
22. Id. at 13.
23. Id at 1. This is not meant to imply that any given stem cell can become all the
types-indeed, it seems that it cannot. In addition, stem cells cannot develop into
embryos or to entire living organisms any more than an isolated sperm or egg can.
24. Michael J. Shamblott et al., Derivation of Pluripotent Stem Cells from Cultured
Human Primordial Germ Cells, 95 PROC. NAT'L ACAD. SCI. 13726, 13726-31 (1998);
James A. Thomson et al., Embryonic Stem Cells Derived from Human Blastocysts, 282
SCIENCE 1145 (1998). Thomson and colleagues obtained hES cells from early embryos
created in the course of infertility treatments voluntarily donated by the gamete donors.
A second method was used by Shamblott and co-workers who isolated human embryonic
germ (hEG) cells-which have properties very similar to hES cells-from human fetal
tissue obtained from terminated pregnancies. In both instances, informed consent was
given for the material to be used in research.
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had independently made the decision to end their pregnancy. Dr.
Gearhart took cells that were precursors of eggs and sperm. These
primordial germ cells were isolated and grown in culture to produce a
pluripotent stem cell line. Although the fetal stem cells developed in
Dr. Gearhart's lab and the embryonic stem cells developed by Dr.
Thomson's lab were derived from different sources, they share many
characteristics including long term self renewal, no chromosomal
abnormalities, and pluripotency 5
Nuclear transfer is a third way that pluripotent stem cells may be
created and isolated. The use of somatic cell nuclear transfer
techniques to produce viable cloned mammals-of which Dolly was
the first26-established that egg cytoplasm could reprogram somatic
cell genetic material into a state of pluripotency-effectively running
the cellular specialization clock backwards. In addition, embryonic
stem cells have been isolated from blastocysts created through
somatic cell nuclear transfer,2 the same procedure used to produce
Dolly. Because somatic cell nuclear transfer potentially allows the
creation of pluripotent stem cells genetically matched to individual
patients, it is heralded as a possible method for developing cell-based
and tissue-based treatments for degenerative disease and injury.
For example, consider a person with progressive heart failure. In
theory, a nucleus from a heart patient's skin cell could be injected
into an egg cell whose own nucleus had been removed. Under
appropriate conditions, the patient's skin cell nucleus could fuse with
the egg cell resulting in the egg behaving as if it had just been
fertilized-undergoing cell division and, with time, becoming a
blastocyst. Stem cells could be isolated from the inner cell mass and a
culture of pluripotent cells created. These cells could then be
stimulated to develop into heart muscle cells. Because the vast
majority of genetic information is contained in the nucleus, these cells
would be essentially identical genetically to the person with the failing
heart. When these heart muscle cells were transplanted back into the
patient, there would likely be no rejection and no need to expose the
patient to immune-suppressing drugs, which can have toxic effects.
Notably, in March of 2002, the first successful use of nuclear
transplantation to treat disease in laboratory mice was reported in the
25. NIH Stem Cell Report, supra note 6, at 14.
26. I. Wilmut et al., Viable Offspring Derived from Fetal and Adult Mammalian Cells,
385 NATURE 810 (1997).
27. See, e.g., Konrad Hochedlinger & Rudolf Jaenisch, Monoclonal Mice Generated by
Nuclear Transfer from Mature B and T Donor Cells, 415 NATURE 1035 (2002); Teruhiko
Wakayama et al., Differentiation of Embryonic Stem Cell Lines Generated from Adult
Somatic Cells by Nuclear Transfer, 292 SC. 740 (2001).
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journal Cell.' The experiments involved mice with severe immune
deficiency. Dr. Jaenisch and colleagues isolated skin cells from the
affected mice. The scientists removed the nucleus from a mouse egg
and replaced it with the nucleus of one of the isolated skin cells. The
fused egg underwent division forming a blastocyst from which stem
cells were isolated. The genetic defect that had made the donor
mouse sick was corrected in the stem cells before the cells were
chemically molded into precursors of immunity producing cells.
Finally, these repaired immune cells were injected into the affected
donor mouse restoring immunity.
Although heralded in the press as a harbinger of the treatments
to come for human degenerative disease, a caveat is in order. Dr.
Jaenisch's group injected 202 enucleated mouse eggs with skin cell
nuclei in order to get a single blastocyst from which stem cells could
be isolated. Obtaining such a large number of human eggs-perhaps
200 per treated patient-would be expensive, difficult, and quite
ethically troubling. However, with remarkably increased efficiency
and fewer ethical edges, this method seems to hold promise for
cellular repair and tissue regeneration in the clinical context.
However, this mouse work itself is quite preliminary and, to date,
there have been no reports of successful somatic cell nuclear transfer
and blastocyst formation using human cells. Jaenisch's work is an
important first step towards regenerative medicine-but it is only the
first step of a long, frustrating, exciting journey.29
What makes pluripotent embryonic stem cells of interest in tissue
regeneration is their ability to undergo further specialization into
specific types of "multipotent" stem cells that are committed to give
rise to cells that have a particular function. An example of such
multipotent cells are hematopoietic stem cells, which give rise to red
blood cells, white blood cells, and platelets-and were the precursor
28. William M. Rideout III et al., Correction of a Genetic Defect by Nuclear
Transplantation and Combined Cell and Gene Therapy, 109 CELL 17 (2002), available at
http://www.cell.com.
29. In addition to possibly holding the key to restoring bodily function through the
replacement of disease affected cells and tissues, there are several additional reasons why
the creation and isolation of human pluripotent stem cells is important to science and
medicine. At the most fundamental level, research on pluripotent stem cells could provide
clarification of the complexities of early human development including: embryogenesis
(i.e., embryo formation) and embryopathy (i.e., disorders of embryo formation), the
biology of human implantation, and the causes of spontaneous abortion. Furthermore,
human pluripotent stem cell research could also dramatically change the way
pharmaceuticals are developed and tested for safety. For example, new medications could
be initially tested on human pluripotent cell lines. This could streamline the process of
pharmaceutical development, as only those compounds found both safe and effective in
such cell line testing would graduate to further testing in laboratory animals and human
subjects.
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cells transplanted into the immune deficient mouse by Jaenisch and
colleagues. Like pluripotent stem cells, these more specialized stem
cells are important in early human development. Unlike pluripotent
cells, multipotent stem cells are found in both children and adults.
For example, consider blood, or hematopoietic, stem cells which
reside in the bone marrow of every child and adult, and can be found
in very small numbers circulating in the blood stream. Blood stem
cells perform the critical role of continually replenishing our supply of
blood cells-red blood cells, white blood cells, and platelets-
throughout life.
There is evidence in mammals that blood stem cells-and other
specialized multipotent cells-can change course and produce skin
cells, liver cells, or cell types other than a blood stem cell or a specific
type of blood cell. For example, experiments in mice suggest that
blood stem cells can generate functioning liver cells." Findings such
as these suggest that even after a stem cell has begun to specialize, the
stem cell may, under certain conditions, be more plastic31 than first
thought."
Research on human adult stem cells suggests that these
multipotent cells have both research and therapeutic potential. For
example, if adult tissue contains multipotent stem cells which are both
self replicating and able to differentiate into a variety of cell types,
then they could be isolated from a heart patient, coaxed into dividing,
directed into becoming heart cells, and re-introduced into the patient.
It is unlikely that they would be rejected since they originated in the
patient and no immunosuppression would be required. The use of
adult stem cells for such cell therapies could reduce or perhaps negate
the use of stem cells from human blastocysts or fetal tissue, sources
that trouble some people on ethical grounds.
While adult stem cells hold promise, there are some very
significant limitations to what may or may not be accomplished with
them. First of all, as previously noted, stem cells from adults have not
been isolated for all tissues of the body. Thus far, adult stem cells
have been identified in brain, bone marrow, blood vessels, skeletal
muscle, cornea, retina, liver, and pancreas.3 3 Notably, adult cardiac
stem cells or adult pancreatic islet stem cells in humans have not been
found. Second, adult stem cells are often present in only minute
30. Eric Lagasse et al., Purified Hematopoietic Stem Cells Can Differentiate into
Hepatocytes Inter Vivo, 6 NATURE MED. 1229 (2000).
31. "Plasticity" refers to the capacity of some adult stem cells to differentiate into
tissues other than the ones from which they originated. NIH Stem Cell Report, supra note
6, at ES-7.
32. Alan Coleman, Somatic Cell Transfer in Mammals: Progress and Applications, 1
CLONING 185 (1999).
33. NIH Stem Cell Report, supra note 6, at ES-6.
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quantities, are difficult to isolate and purify, and their numbers may
decrease with age. A significant limiting factor in the potential of
adult stem cells in regenerative medicine is the insufficient numbers
of cells available for transplant.' Finally, current evidence indicates
that adult stem cells have a limited capacity to give rise to many
different specialized cell types.35
Any attempt to use stem cells from a patient's own body for
treatment would require that stem cells be isolated from the patient
and grown in culture in sufficient numbers for therapeutic use. For
some acute disorders, there may not be enough time to grow a
sufficient number of cells. In other disorders, caused by a genetic
defect, the genetic error would likely be present in the patient's stem
cells. In addition, adult stem cells may contain genetic abnormalities,
caused by daily living and by "errors" made in gene replication during
the course of a lifetime.36 These potential weaknesses could limit the
usefulness of adult stem cells.
Although there has been great enthusiasm in the media over the
isolation of stem cells, the case can be overstated.' Consider, for
example, the fervor over the claim of Anthrogenesis Corporation to
have derived "embryonic stem cells" from placenta.' Notably,
articles describing the research including the use of cell markers to
confirm that these cells are stem cells-either pluripotent or
multipotent-have not been published. Stem cells may have been
isolated from placenta, but what type and what is their capacity to
differentiate into other cells types? It is a mistake at this point to
think of placental derived cells as replacements for embryonic stem
cells or to conclude that no further research is needed with
pluripotent cells or other multipotent cell types.
Absent sufficient evidence that adult stem cells have the broad
potential characteristic of pluripotent stem cells, it is prudent to study
the developmental capability of adult stem cells alongside that of
pluripotent stem cells. It is too early to say whether one type of stem
cell or the other will prove best for a given disease or injury; but it is
probably reasonable to say that one cell type will not be sufficient for
all regenerative needs. It may be that stem cells from adult tissue will
34. Id.
35. Id. at ES-9 to ES-10.
36. Andrew J.G. Simpson, The Natural Somatic Mutation Frequency and Human
Carcinogenesis, 71 ADVANCES IN CANCER RES. 209,227-31 (1997).
37. This is a trap into which reports on either adult or embryonic stem cells can
tumble. There is a political agenda at work that tends to obfuscate the actual costs,
benefits, and potentialities of both adult stem cell and embryonic stem cell research in the
interest of persuasive rhetoric.
38. Nicholas Wade, A New Source for Stem Cells is Reported, N.Y. TIMES, Apr. 12,
2001, at A25.
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prove useful in the treatment of some diseases, fetal stem cells for
others, and embryonic stem cells for others. It is simply too soon to
tell. The answers lie in the research ahead.
Scientifically, it seems prudent at this time to proceed-albeit
with caution-to: (1) determine the optimal conditions for isolation
and culture of both human embryonic and adult stem cells; (2) define
which particular diseases are best treated by pluripotent stem cells
and which by multipotent stem cells; and, (3) discover the factors
which will induce stem cells-both pluripotent and multipotent-to
differentiate into the desired cell type, e.g., neurons or heart cells. In
parallel, animal models can: (1) supply data for optimizing human
cell experiments; (2) address safety concerns, both in tissue
development and in transplantation; and, (3) assess the outcomes of
using stem cell transplants for given diseases and injuries.
H. The Ethics and Public Policy of Nuclear Transplantation
and Stem Cell Research
A. "What's in the Dish?"
Embryonic stem cell science in general, and the making of
blastocysts through nuclear transfer in particular, raises cavernous
limit questions-questions of ethics which science cannot, indeed
ought not, answer. The prime area of ethical disquiet is the question
of the moral status of human blastocysts Is a human blastocyst a
new person whose life merits protection, or an emergent being
without tangible interests and unable to make a strong moral claim
for protection, or is a human blastocyst something else entirely?'4
The argument for full protection is predicated on considering the
human blastocyst as a full human person possessing the full moral
rights and protections of personhood. Hence, any action resulting in
direct harm to the blastocyst may not be undertaken even in pursuit
of the goods of human health. In contrast to the full personhood view
is the developmental view of moral status, which posits that a human
acquires interests, rights, and roles incrementally as sentience,
consciousness, and relationships develop and justify these safeguards.
On this view, the blastocyst may be accorded respect and value, but
39. The moral status of the blastocyst vas a primary area of ethical inquiry for the
Advisory Committee. Other ethical concerns regarding "non-reproductive cloning"
considered by the Committee were: risk/benefit analysis, the slippery slope, potential
exploitation of egg donors, and distributive justice. See CLONING CALIFORNIANS?, supra
note 1, at 1183-89.
40. This concern is not unique to nuclear transplantation of course. Any type of work
using human embryos-from treating infertility to studying embryogenesis to deriving
stem cells-raises the moral status question.
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can be destroyed for good reason. Finally, perhaps the blastocyst
created and housed in a laboratory has no claim to either full or
developing moral status, as there is no potential ex utero to develop
into a child. McGee and Caplan have labeled this dilemma as the
"what is in the dish" problem.
Recognizing that embryonic cell status is not a scientific matter,
they argue that embryonic stem research itself radically changes the
problem of defining basic facts about human embryos. For example,
the very isolation of human gametes and blastocysts from their
biological environments causes these cells to "take on different
meanings, depending on the institutional context., 42 For example, in
the medical context, frozen sperm, eggs, and embryos can become
"treatments" for infertility or "property" to be awarded in divorce or
probate proceedings. In creating blastocysts in the laboratory-
whether potentially to treat infertility or potentially to treat heart
failure-cells that were once of use only within the human body have
become of use outside of that context. Hence, whatever moral status
blastocysts may have in the body may be only an "indicator" of their
status "in the dish." This is further complicated by the changing
nature of the cells in the dish.
The changing nature of what is in the dish is obvious. It was not
long ago that Western society and particularly the United States
debated the status of ordinary embryos. At that time, the single-
cell human embryo was fairly well understood to be the product of
conception, and its ordinary end, birth. Today, stem cells, gametes,
embryos, and tissues from humans and animals can be combined in
unusual ways without conception, and potentially brought to birth.
... [Tjhe point here is that we can in no way infer what ought to be
done with these new technologies from a scientific analysis of
embryo or fetal development. What an embryo or fetus is, is
changing.43
Not only can an "ought" not be derived from an "is," what in fact
"is" is in flux. McGee and Caplan suggest a move away from the
developmental view of moral status and an engagement in public
conversation about the changing nature of human reproduction and
the changing definition of "reproductive material."'
But, although patently necessary, public engagement does not
seem enough. Ethics requires raising the question behind the
question. The moral status "answer" is given to the "what's in the
dish" question. However, the prior question-the question behind
41. Glenn McGee & Arthur L. Caplan, What's in the Dish?, 29 HASTINGS CENTER
REP. 36,37 (1999).
42. Id.
43. Id. at 38.
44. Id.
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the question-is why are we worried about the contents of the dish in
the first place? Are we once again seeking to discover what makes us
human and to lay claim to that? Are we troubled by the abortion
question or the possibility of germ-line genetic engineering? Are we
afraid of "playing God?" Are we lured by hopes of human health
and well-being? Are we fulfilling mandates to heal and to care?
And, in infinite regression, there are questions behind these
questions: Is there good to be gained, right to be done, harm to be
avoided, promises to be kept, justice to be meted out? Not knowing
just what a blastocyst is leaves duties towards these entities hazy and
ill-defined. There seems to be an assumption that once the moral
status of the embryo is clearly defined what is to be done will be
unmistakable. Perhaps-but it is not likely. Indeed, there is moral
myopia inherent in allowing the dish dilemma to be the sole arena of
inquiry regarding nuclear transplantation. First, it reflects a general
fascination with the ethics of the "materials and methods" of
research, without imagining the "results and conclusions." It does not
engage the question behind the question-the question of what is
down the path of inquiry we choose to follow. Who will benefit, and
at what cost? Who will be harmed, and at what gain? Will an even
deeper trench between the medical haves and have-nots be dug? "No
one doubts that [actor and Parkinson's afflicted] Michael J. Fox will
receive stem cell therapy should it become available. But will the
poor and middle class around the world indeed benefit?"45 Second,
moral myopia cannot, by definition, bring the question behind the
question into focus-the question not of what is the case, but of what
ought to be the case. Laurie Zoloth elaborates: "What is at the heart
of the issue [of using embryos to create stem cells] is to ask: Are
some things so important to human advancement that we have a
responsibility to pursue them? Who are we if we turn away, who are
we if we proceed?,
46
B. Promises, Promises
The enormous medical potential of research on stem cells in
general and nuclear transplantation in particular is a forceful and
persuasive incentive to continue. However, despite all of the
promises that the fruits of embryonic and adult stem cell research and
nuclear transplantation are ripe for the picking, the primary
beneficiaries of regenerative medicine in all likelihood will not be
contemporary advocates, Michael J. Fox and paralyzed Christopher
45. Vanessa T. Kuhn, Stem cells: Equity or Ownership?, 2 AM. J. OF BIOETHICS 1, 2
(2002).
46. Laurie Zoloth, Jordan's Banks, A View from the First Years of Human Embryonic
Stem Cell Research, 2 AM. J. OF BIOETHICS 3,7 (2002).
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Reeve, but ill and injured future persons. Sobering as it may be, there
are no known once-ill-now-healthy beneficiaries of stem cell and
nuclear transplantation research. What is possible today is small,
steady down payments on a future that, no matter how bright, is
ultimately unknowable.
One of the basic tenants of medical ethics is the right to informed
consent. Using understandable language and description, medical
professionals are obligated to tell patients the truth about their
condition. Truth telling respects autonomy and sets the parameters
for informed choice. In cases of life threatening illness, the truth is
framed so as to mitigate against unrealistic expectations for cure. For
example, a cancer patient ought not to be told that there is a
"wonderful chance" of cure with an exotic and burdensome
procedure known to succeed in like cases less than 5% of the time.
Current stem cell rhetoric hovers dangerously close to violating the
public's right to informed consent and choice. Creating false hope is
wrong at the bedside and is wrong in the public square. A
particularly troubling example is the comments of Michael West,
CEO of Advanced Cell Technology, after testifying before an
appropriations subcommittee of the Senate in December 2001. West
is quoted by New York Times Syndicate reporter, Judy Holland, as
saying that "a six-month moratorium on human cloning [i.e., nuclear
transplantation] could lead to the loss of 3,000 lives a day because
that many people die from degenerative diseases that could
potentially be treated."47 This quote illustrates what Rebecca Dresser
calls the instigation of "unrealistic optimism."' Such overstating of
the facts of the matter is wrong because it disrespects the moral
agency of patients and the public. It is simply impossible to have off-
the-shelf tissue therapies to save a single life-let alone 3,000 lives-
within months. To say so is disingenuous at best and intentionally
misleading at worst. Either way, it is to be avoided.
If we seek to have a serious, on-going public deliberation about
stem cells, nuclear transplantation, and other human biotech
innovations, as the Advisory Committee strongly recommends, 49 then
the truth about stem cells must be told. Research on stem cells and
nuclear transplantation is just beginning.0 There are no therapies, no
cures, no clinical trials. There is potential and there is hope but there
47. Judy Holland, Biotech Firm Expects to Make Tissue from Stem Cells in Six Months,
N.Y. TIMES SYNDICATE, Dec. 5,2001, available at www.RNAture.com.
48. Rebecca Dresser, Embryonic Stem Cells: Expanding the Analysis, 2 AM. J. OF
BIOETHICS 40,41 (2002).
49. See CLONING CALIFORNIANS?, supra note 1, at 1146, 1191-92.
50. This includes embryonic cells obtained from donated embryos and those obtained
after nuclear transplantation as well as adult stem cells. At one time or another all have
been oversold to the public.
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are no guarantees. It is incumbent on those whom the public views as
"experts"-scientists, biotech CEOs, legislators, corporate attorneys,
patient advocates, journalists, bioethicists (especially those who
consult in the bioscience boardroom)-to do no harm, which counsels
truth telling and the avoidance of hype in the public square. Only
then can responsive and responsible public conversation ensue as we
"come to grips with the new dilemmas posed by rapid advances in our
understanding of human biology."51
C. Moral Imagination and Social Justice
Moral imagination has been described as "the capacity to
empathize with others and to discern creative possibilities for ethical
action, ' taking sympathetically the perspective of those affected by a
decision. In thinking about stem cell research in general and nuclear
transplantation in particular, who is it that warrants empathy? Let
me suggest that it is not primarily the ill or injured who will
potentially benefit in the future from the ripening of the fruits of
current research on regenerative medicine-although empathy,
understanding, care, and compassion are surely owed to them.
However, the prime recipients of our empathic understanding ought
to be those who reside on the margins of health care today-those
without the basics of nutrition and medical care; those whose lives are
riddled with violence and abuse; those who have no other voice but
ours in the public square. If stem cell technologies are, as has been
claimed, the most significant medical breakthrough since sanitation
and antibiotics, how can we assure that our empathy embraces those
who today lack plumbing and pills?
It is likely that the research necessary in order to realize "the
enormous medical promise of stem cells to relieve human suffering"'
will be expensive. And, if the therapeutic dream comes true, the
tissue-based treatments for degenerative disease and injury will be
dear. But, even if the cost question is equitably addressed, there is
another question lurking behind; that is, whether we ought to
consume precious resources-time, money, intellectual energy-on
such research when 2 million of California's youngest residents have
no consistent access to cough medicine, vaccinations, and antibiotics.
A road taken always leaves a road untrod. Will pursuing the
path of regenerative medicine further marginalize those already
disadvantaged by the current healthcare (un)system? Does exercising
empathy for those on the margins require traipsing a different path
or, perhaps, erecting a bridge between high tech research and access
51. CLONING CALIFORNIANS?, supra note 1, at 1193.
52. Thomas E. McCollough, THE MORAL IMAGINATION AND PUBLIc LiE 16 (1991).
53. CLONING CALIFORNIANS?, supra note 1, at 1188.
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to low tech health care? Note that I am not suggesting that stem cell
and nuclear transplantation research be forfeited-the promise is
simply too great. What I am suggesting is that the down payment on
the future of stem cells is due and payable today to those living on the
margins of health, especially children.
Moral imagination asks not only for empathy but also for
imaginatively perceiving opportunities for acting. One such
opportunity would be to construct a health care vision for the state,
one that includes the health and well-being of every Californian.
Such a vision would, first, provide a justice-based framework for
deciding to what extent to pursue particular biotech innovations5 6 and,
second, guarantee that those who have no other voice but ours are
heard and benefited by the road taken.
Conclusion
The ethical concerns regarding nuclear transplantation and
embryonic stem cell research are not exhausted by a consideration of
moral status. I have raised two other areas of concern-informed
consent in the public square and social justice. There are others.
It is not merely stem cell science that is complex. Stem cell ethics
is-as is the green ogre Shrek57-complex "like an onion"'s with layer
upon layer upon layer of questions. I have modestly proposed these
two for your consideration.
54. See MARK JOHNSON, MORAL IMAGINATION: IMPLICATIONS OF COGNITIVE
SCIENCE FOR ETHICS 202 (1993).
55. A national health care vision is also sorely needed but there is a profound lack of
political will on the issue of health and health care.
56. For a discussion of "clone age justice," see Margaret R. McLean, Much Ado About
Cloning in the Public Square, 32 U. TOL. L. REV. 337,347-49 (2001).
57. SHREK (DreamWorks 2001).
58. Id.
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